Eli Radiopharma Completes Series A Financing of Nearly RMB 400 Million to Advance Innovative Radiopharmaceutical Pipeline Toward Clinical Development

Résumé détaillé

HANGZHOU, China, Nov. 11, 2026 /PRNewswire/ -- Hangzhou Eli Radiopharma Co., Ltd. ("Eli Radiopharma", or "the Company"), an innovative radiopharmaceutical company focused on…

HANGZHOU, China, Nov. 11, 2026 /PRNewswire/ -- Hangzhou Eli Radiopharma Co., Ltd. ("Eli Radiopharma", or "the Company"), an innovative radiopharmaceutical company focused on integrated diagnostics and therapeutics for oncology and neurological diseases, today announced the completion of a Series A financing round of nearly RMB 400 million. The round was led by Huagai Capital, with Bayland Capital as co-lead investor, and participation from Boyu Ventures, Delian Capital, InnoPinnacle Fund, Haibang Venture, Bairui Capital, Shenzhen Angel FOF Management, and Grand Flight Investment.

The proceeds will primarily support the advancement of the Company's core innovative pipeline toward clinical development. Funding will be directed toward preclinical research, clinical trial applications, and early-stage clinical development, alongside further investment in R&D platforms, talent acquisition, and the Company's clinical and business development. The financing will provide strong support for the continued advancement of the Company's pipeline and its long-term growth. To date, the Company has advanced multiple programs targeting novel molecular targets through lead discovery and in vitro and in vivo validation, with promising target specificity and drug development potential.

"The completion of this financing round marks an important milestone in Eli Radiopharma's development and reflects our investors' confidence in our R&D strategy, technological capabilities, and long-term vision," stated Dr. Feng Yu, Founder and CEO of Eli Radiopharma. "Moving our pipeline toward the clinic is a critical next step in translating our research into meaningful advances for patients. This financing will support our efforts to advance our lead programs through preclinical development and regulatory milestones, bringing differentiated radiopharmaceutical candidates closer to clinical evaluation.

Cynix Wang, Chief Investment Officer of Healthcare at Huagai Capital, said, "Radiopharmaceuticals…

Début de l'article, extrait de PR Newswire. Pour lire la suite, ouvrez l'article chez le média.